Clinical trial
Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed…
NCT00062660 · Boehringer Ingelheim, Industry · Approved for marketing
Key facts
| NCT number | NCT00062660 |
|---|---|
| Title | Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection |
| Official title | An Open Label Safety Study to Evaluate the Safety of Tipranavir Plus Ritonavir When Used in Combination With Other Agents for the Treatment of Patients With HIV Infection Who Have Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited Treatment Options |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Tipranavir |
| Start date | May 1, 2003 |
| Primary completion | Apr 1, 2014 |
| Completion | Apr 1, 2014 |
| First posted | Jun 12, 2003 |
| Last update posted | Nov 30, 2016 |
| Countries | Australia, Belgium, Denmark, France, Greece, Ireland, Italy, Portugal, South Africa, Switzerland, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: